Related Experiment Video

Updated: May 16, 2025

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.7K

Risk of Ophthalmotoxicity Associated with Antibody-Drug Conjugates: A Systematic Review and Meta-analysis

Xin Feng1,2, Xiaoxia Yu1,3, Shan Yang1,3

  • 1Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, 107 Yanjiang West Road, Guangzhou, 510120, People's Republic of China.

Clinical Drug Investigation
|May 14, 2025
PubMed
Abstract

Insights

Antibody-drug conjugates (ADCs) increase cancer therapy benefits but pose an elevated risk of eye toxicity. This study quantines the prevalence and risk of ophthalmotoxicity in patients receiving ADCs.

Area of Science:

  • Oncology
  • Ophthalmology
  • Pharmacology

Background:

  • Antibody-drug conjugates (ADCs) offer significant advantages in cancer therapy.
  • However, the associated ophthalmotoxicity of ADCs is not well understood.
  • This study addresses the knowledge gap regarding ADC-induced ocular adverse events.

Purpose of the Study:

  • To determine the prevalence and risk of ophthalmotoxicity in patients undergoing antibody-drug conjugate therapy.
  • To identify specific ADC payloads associated with increased ocular toxicity.
  • To analyze the most frequent ocular manifestations of ADC therapy.

Main Methods:

  • Systematic literature search of phase II/III randomized clinical trials (RCTs) up to March 2025.
  • Inclusion of 31 RCTs with 18,490 patients.
  • Meta-analysis of ocular adverse events using risk ratios (RR) and 95% confidence intervals (CIs).

Main Results:

  • The pooled incidence of all-grade ocular adverse events was 10.45%.
  • Antibody-drug conjugates were associated with an increased risk of ophthalmotoxicity (RR = 1.76).
  • Monomethyl auristatin E and F payloads showed higher risks (RR = 2.73 and 3.01, respectively); dry eye was most common (15.49%).

Conclusions:

  • Antibody-drug conjugate therapy is linked to a significantly elevated risk of ophthalmotoxicity.
  • Further research is required to elucidate the impact of ADC components and treatment variables on ocular toxicity.
  • Understanding these factors is crucial for managing ADC-related eye complications in cancer patients.

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

638

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

Overview
30.9K
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
481
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
368
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
397
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
979